Tubulin Polymerization-IN-40 is an acridane-based inhibitor that potently disrupts tubulin polymerization, exhibiting an IC50 of 1.5 μM. It halts cancer cell progression at the G2/M phase, triggers apoptosis, and possesses anti-cancer properties along with immunopotentiating effects [1].

Tubulin polymerization-IN-40 (Compound NT-6) exhibited significant antiproliferative efficacy against four cancer cell lines (HCT-116, B16-F10, HeLa, HepG2), with an average IC50 of 30 nM [1]. At concentrations of 10, 25, and 50 nM administered over 48 hours, it effectively induced apoptosis in B16-F10 cells [1]. Furthermore, Tubulin polymerization-IN-40 caused a G2/M phase arrest in B16-F10 cells at the same concentrations after 24 hours [1]. The compound also significantly inhibited colony formation of B16-F10 cells at 50 nM, reducing formation almost completely after 24 hours of treatment [1]. Additionally, Tubulin polymerization-IN-40 dose-dependently inhibited the migration of B16-F10 cells at concentrations of 10, 25, and 50 nM over 24 hours [1].

Tubulin polymerization-IN-40 (Compound NT-6; 10 mg/kg; intraperitoneal administration; daily; for 14 days) demonstrated remarkable antitumor efficacy in a melanoma model. When combined with NP-19 (10 mg/kg; intraperitoneal administration), Tubulin polymerization-IN-40 significantly reduced tumor burden (TGI%=77.6%) and enhanced antitumor immune responses [1].